Sobi, Apellis win EU nod for Aspaveli against rare kidney...

2026-01-16 07:39:06 ET More on Sobi, Apellis Pharmaceuticals Swedish Orphan Biovitrum AB (publ) (SWOBY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow Apellis Pharmaceuticals, Inc. (APLS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript Apellis targets 225 EMPAVELI start forms by year-end amid steady SYFOVRE growth and expanded rare kidney launch Apellis Pharmaceuticals Q3 2025 Earnings Preview Read the full article on Seeking Alpha For further details see: Sobi, Apellis win EU nod for Aspaveli against rare kidney diseases